By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors VISHWAKARMA, Ram; KUMAR, Ajay; KHAN, Inshad Ali; BHARATE, Sandip Bibishan; JOSHI, Prashant; SINGH, Samsher; SATTI, Naresh, filed on October 21, 2015, was made available online on October 5, 2017, according to news reporting originating from Washington, D.C., b
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors LIU, Wai Leung; PURKINS, Lynn; YEADON, Michael, filed on June 9, 2017, was made available online on October 5, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application has not been assigned to a com
Mayo Clinic issued the following news release:. Mayo Clinic will have the first clinical 7- Tesla MRI scanner in North America that has been cleared by the U.S. Food and Drug Administration. Mayo Clinic will be the first medical center in North America to offer patients advanced diagnostic imaging using an MRI scanner with the strongest magnetic fi
-The worlds most progressive pharmaceutical companies, CROs and sites will continue to advance beyond the clinical trial status quo at the 2017 DrugDev Summit in Philadelphia, November 7-8. Co-chaired by Novartis and CSL Behring, DrugDevs annual Summit is widely regarded by customers as the premier open forum for sharing clinical trial best practic
Office Address: U.S. Department of Veterans Affairs; Office of Acquisition Operations; Strategic Acquisition Center; 10300 Spotsylvania Ave| STE 400; Fredericksburg VA 22408-2697. Subject: 65 Acquisition of Medical Surgical Prime Vendor Supplies. 10300 Spotsylvania Ave, Suite 400.
PRESIDENT Donald Trump and Republicans in Congress have brought chaos to the US health care system by trying to destroy the Affordable Care Act and failing to reauthorise the Children's Health Insurance Program, which, with bipartisan support for the past 20 years, has provided care for millions of children. In an ideal world, Congress would quickl
Excluding specified items, adjusted diluted EPS from continuing operations was $0.66 in the third quarter, at the high end of the previous guidance range of $0.64 to $0.66. In September, Abbott received U.S. FDA approval for its FreeStyle Libre glucose monitoring system as a replacement1 for finger stick blood glucose monitoring. During the quarter
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical, today announced its clinical data presentation on the safety and efficacy of DSUVIA?, 30 mcg classified by age group across four clinical trials at the American Society of Anesthesiologists' ANESTHESIOLOGY 2017 Annual Meeting. The information presented during the session was authored
By a News Reporter-Staff News Editor at Health& Medicine Week ADM Tronics Unlimited, Inc. is in the final stage of developing the Alvio? device, a new technology it has had under development pursuant to its previously announced agreement with QOL Devices, Inc.. "It is exciting to see the Alvio approaching commercialization," stated Bez Arkush,
Oct. 20 The U.S. Senate battle over Obamacare repeal put Alaska Gov. Walker instead took a planned trip to China for meetings on his Alaska natural gas pipeline project. But the governor sent a team of seven to work with the White House to assess the impact of the bill on Alaska.
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that the results of the APOLLO Phase 3 study of patisiran in hereditary ATTR amyloidosis patients with polyneuropathy, as well as additional posters on patisiran and hATTR amyloidosis, will be presented at the 1 st European ATTR Amyloidosis Meeting for Patients an
CAMBRIDGE, Mass.- Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today announced an exclusive licensing agreement with Vir Biotechnology, a company dedicated to transforming the care of people with serious infectious diseases, for the development and commercialization of RNAi therapeutics for infectious diseases, including...
The market leader is Danish company Novo Nordisk, followed by the UK' s Shire and Germany' s Bayer. One of the trends shaping the market is an increase in product approvals for hemophilia. The increase in the number of drug approvals for hemophilia by the regulatory bodies such as FDA in the US is an emerging trend in the market. For instance, in J
-Arcturus Therapeutics, Inc., a leading RNA medicines company, announced today that it has entered into a research collaboration and worldwide license agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson& Johnson. The deal was facilitated by the Johnson& Johnson Innovation center, in California.
Asia-Pacific Medical Suction Device, by Types by Usage, by Suction parts- Forecast to 2023. Executive Summary Market Research Future published new report, titled "Medical Suction Device Market- Research Report: Asia and Pacific Forecast to 2023". Market Synopsis ofMedical Suction Device Market: Market Scenario:.
AstraZeneca and Merck& Co., Inc., today announced that the US Food and Drug Administration has accepted and granted Priority Review for a supplemental New Drug Application for the use of Lynparza tablets in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuva
AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration has accepted a supplemental Biologics License Application for Imfinzi for the treatment of patients with locally advanced unresectable non-small cell lung cancer whose disease has not progressed following platinum..
Atara Biotherapeutics, Inc., a leading "off-the-shelf", or allogeneic, T-cell immunotherapy company developing novel treatments for patients with cancer and autoimmune diseases, announced today that the Company initiated a multinational, multicenter Phase 1 clinical study to evaluate allogeneic ATA188 in patients with progressive or...
AtriCure, Inc., a leading innovator in surgical treatments for atrial fibrillation and left atrial appendage management, today announced that it will present at the Stifel Healthcare Conference at the Palace Hotel in New York on Tuesday, November 14, 2017. AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditi
According to a new market research report " Autosamplers Market by Product (Systems (Liquid Chromatography, GC (Liquid, Headspace, All-in-one)), Accessories (Syringe& Needle, Vial, Septum)& Enduser (Pharmaceutical companies, Oil& Gas, Food& Beverage, Environment testing)- Global Forecasts to 2022", published by MarketsandMarkets?, the market is p
B. Braun Medical Inc. will present its expanding portfolio of regional anesthesia products at ANESTHESIOLOGY 2017, the American Society of Anesthesiologists Annual Meeting, Oct. 21-23, in Boston. New products designed to improve efficiency and patient outcomes will be showcased, including: Xperius Ultrasound System; SAXA Anesthesia Disinfectio
This report studies Electrodes for Medical Devices in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022.. This report focuses on top manufacturers in global market, with production, price, reve
This report studies Orthopedic Prosthetic Implants in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022.. This report focuses on top manufacturers in global market, with production, price, reve
BioLife Solutions, Inc., the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, today announced that its customer Kite Pharma, Inc., a wholly-owned subsidiary of Gilead Sciences, has received US FDA approval for Yescarta, the first CAR T-cell therapy for.
For seven years, congressional Republicans and Democrats battling over ObamaCare have agreed on only one thing: They couldn't agree on anything. As insurers narrowed networks of doctors and hospitals or abandoned states entirely, Congress flailed. Five days after Trump's declaration- a blink of an eye in Congress- time- Republican Sen.